MX2023001292A - Mimeticos de hepcidina conjugados. - Google Patents
Mimeticos de hepcidina conjugados.Info
- Publication number
- MX2023001292A MX2023001292A MX2023001292A MX2023001292A MX2023001292A MX 2023001292 A MX2023001292 A MX 2023001292A MX 2023001292 A MX2023001292 A MX 2023001292A MX 2023001292 A MX2023001292 A MX 2023001292A MX 2023001292 A MX2023001292 A MX 2023001292A
- Authority
- MX
- Mexico
- Prior art keywords
- conjugated
- hepcidin mimetics
- hepcidin
- mimetics
- methods
- Prior art date
Links
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 title abstract 2
- 102000018511 hepcidin Human genes 0.000 title 1
- 229940066919 hepcidin Drugs 0.000 title 1
- 108060003558 hepcidin Proteins 0.000 title 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona análogos de hepcidina con mejores semividas in vivo, y composiciones farmacéuticas relacionadas y métodos de uso de estos.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063057582P | 2020-07-28 | 2020-07-28 | |
| US202063057583P | 2020-07-28 | 2020-07-28 | |
| US202063057574P | 2020-07-28 | 2020-07-28 | |
| US202063057577P | 2020-07-28 | 2020-07-28 | |
| US202163169515P | 2021-04-01 | 2021-04-01 | |
| US202163169527P | 2021-04-01 | 2021-04-01 | |
| US202163169533P | 2021-04-01 | 2021-04-01 | |
| PCT/US2021/043581 WO2022026631A1 (en) | 2020-07-28 | 2021-07-28 | Conjugated hepcidin mimetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001292A true MX2023001292A (es) | 2023-02-22 |
Family
ID=80036079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001292A MX2023001292A (es) | 2020-07-28 | 2021-07-28 | Mimeticos de hepcidina conjugados. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20240066131A1 (es) |
| EP (2) | EP4188412A1 (es) |
| JP (2) | JP2023540679A (es) |
| KR (1) | KR20230053615A (es) |
| AU (2) | AU2021316000A1 (es) |
| CA (2) | CA3188410A1 (es) |
| IL (1) | IL299530A (es) |
| MX (1) | MX2023001292A (es) |
| WO (3) | WO2022026629A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9822157B2 (en) | 2013-03-15 | 2017-11-21 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| DK3143037T3 (da) | 2014-05-16 | 2021-09-20 | Protagonist Therapeutics Inc | Alpha4beta7-integrin-thioether-peptidantagonister |
| EP3169403B1 (en) | 2014-07-17 | 2024-02-14 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US11753443B2 (en) | 2018-02-08 | 2023-09-12 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| JP7441955B2 (ja) | 2020-01-15 | 2024-03-01 | ヤンセン バイオテツク，インコーポレーテツド | インターロイキン２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用 |
| MX2023005994A (es) | 2020-11-20 | 2023-08-11 | Janssen Pharmaceutica Nv | Composiciones de inhibidores peptidicos del receptor de interleucina-23. |
| MX2023008330A (es) | 2021-01-20 | 2024-01-18 | Viking Therapeutics Inc | Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos. |
| WO2022212698A1 (en) * | 2021-04-01 | 2022-10-06 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5993811A (en) * | 1997-02-03 | 1999-11-30 | Biology Associates, Llc | Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis |
| AU2015243990A1 (en) * | 2014-04-07 | 2016-11-10 | La Jolla Pharmaceutical Company | Hepcidin mimetic peptides and uses thereof |
| US20190002503A1 (en) * | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| WO2018128828A1 (en) * | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Novel hepcidin mimetics and uses thereof |
| US11753443B2 (en) * | 2018-02-08 | 2023-09-12 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
-
2021
- 2021-07-28 US US18/018,481 patent/US20240066131A1/en active Pending
- 2021-07-28 AU AU2021316000A patent/AU2021316000A1/en active Pending
- 2021-07-28 MX MX2023001292A patent/MX2023001292A/es unknown
- 2021-07-28 WO PCT/US2021/043579 patent/WO2022026629A1/en unknown
- 2021-07-28 CA CA3188410A patent/CA3188410A1/en active Pending
- 2021-07-28 JP JP2023505864A patent/JP2023540679A/ja active Pending
- 2021-07-28 US US18/018,482 patent/US20240018189A1/en active Pending
- 2021-07-28 US US18/016,825 patent/US20230295259A1/en active Pending
- 2021-07-28 WO PCT/US2021/043581 patent/WO2022026631A1/en active Application Filing
- 2021-07-28 WO PCT/US2021/043584 patent/WO2022026633A1/en active Application Filing
- 2021-07-28 AU AU2021315564A patent/AU2021315564A1/en active Pending
- 2021-07-28 CA CA3189432A patent/CA3189432A1/en active Pending
- 2021-07-28 EP EP21848536.5A patent/EP4188412A1/en active Pending
- 2021-07-28 EP EP21849116.5A patent/EP4188413A1/en active Pending
- 2021-07-28 KR KR1020237006472A patent/KR20230053615A/ko unknown
- 2021-07-28 JP JP2023505923A patent/JP2023536463A/ja active Pending
- 2021-07-28 IL IL299530A patent/IL299530A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4188413A1 (en) | 2023-06-07 |
| AU2021315564A1 (en) | 2023-02-09 |
| US20240018189A1 (en) | 2024-01-18 |
| CA3188410A1 (en) | 2022-02-03 |
| US20240066131A1 (en) | 2024-02-29 |
| CA3189432A1 (en) | 2022-02-03 |
| WO2022026629A1 (en) | 2022-02-03 |
| WO2022026631A1 (en) | 2022-02-03 |
| IL299530A (en) | 2023-02-01 |
| WO2022026633A1 (en) | 2022-02-03 |
| AU2021316000A1 (en) | 2023-02-16 |
| EP4188412A1 (en) | 2023-06-07 |
| US20230295259A1 (en) | 2023-09-21 |
| KR20230053615A (ko) | 2023-04-21 |
| JP2023536463A (ja) | 2023-08-25 |
| JP2023540679A (ja) | 2023-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001292A (es) | Mimeticos de hepcidina conjugados. | |
| MX2022002633A (es) | Mimeticos de hepcidina conjugada. | |
| PH12020551261A1 (en) | Il-15 conjugates and uses thereof | |
| PH12020500241A1 (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
| MX2020007148A (es) | Formulaciones. | |
| MX2021002180A (es) | Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso. | |
| MX2021006912A (es) | Composiciones para la administracion de agentes terapeuticos y metodos de uso y fabricacion de las mismas. | |
| MX2018002723A (es) | Macrociclicos peptidomimeticos y usos de los mismos. | |
| MX2019011329A (es) | Composiciones novedosas y metodos. | |
| MX2022001776A (es) | Terapias de combinacion de inmuno oncologia con conjugados de il-2. | |
| MX2021013581A (es) | Composiciones de nanoemulsiones que comprenden ingredientes biologicamente activos. | |
| PH12020551716A1 (en) | Anti-ror antibody constructs | |
| PH12021550611A1 (en) | Interleukin 10 Conjugates and Uses Thereof | |
| MX2019013485A (es) | Composiciones para el cuidado bucal y metodos de uso. | |
| MX2020009733A (es) | Composiciones. | |
| MX2022007981A (es) | Derivados de polieter, usos y metodos para hacer los mismos. | |
| MX2021003773A (es) | Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos. | |
| ZA202107825B (en) | Pharmaceutical parenteral composition of dual glp1/2 agonist | |
| PH12021550289A1 (en) | Ox40-binding polypeptides and uses thereof | |
| CO2022003156A2 (es) | Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15rα y su uso | |
| WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| JOP20210008A1 (ar) | أنواع أبيراز مذابة، وطرق لاستخدامها | |
| MX2022006312A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
| MX2021015846A (es) | Derivados de antraciclina. |